Galapagos enters deal to boost decentralised CAR-T therapy production
17 May 2024
Cell TherapyLicense out/inClinical StudyImmunotherapyBreakthrough Therapy
Preview
Source: Pharmaceutical Technology
Galapagos’ decentralised manufacturing platform is designed to deliver fresh, fit cells with a median vein-to-vein time of just seven days. Credit: Matveev Aleksandr / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Galapagos has signed a strategic partnership with Blood Centers of America (BCA) to expedite the decentralised production of its chimeric antigen receptor (CAR)-T cell therapies across the US.
This strategic partnership will utilise BCA’s extensive network, spanning over 50 community blood centres in 43 states.
The deal will facilitate in the good manufacturing practice (GMP)-compliant manufacturing of Galapagos’ CAR-T haemato-oncology clinical programme.
Galapagos will also access apheresis capacity at BCA sites when required.
Preview
Source: Pharmaceutical Technology
Preview
Source: Pharmaceutical Technology
BCA will play a vital role in coordinating site initiation and onboarding processes, which will help Galapagos speed up its manufacturing efforts and maintain consistent quality across all locations.
Galapagos’ decentralised manufacturing platform is designed to deliver fresh, fit cells with a median vein-to-vein time of just seven days.
“Working with BCA’s extensive nationwide network allows us to efficiently scale up decentralised CAR-T therapy manufacturing across the US, while their established infrastructure helps us harmonise operations and access apheresis capacity.
“This agreement complements the existing collaborations between Galapagos and Landmark Bio and Thermo Fisher Scientific and translates to a significant step forward in our aspiration to bring CAR-T therapies to more patients with a vein-to-vein time of just seven days.”
The latest development comes after Galapagos and BridGene Biosciences entered a strategic partnership and licensing deal for the discovery of new small-molecule drug candidates for oncology targets.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.